JP2015534981A5 - - Google Patents

Download PDF

Info

Publication number
JP2015534981A5
JP2015534981A5 JP2015537809A JP2015537809A JP2015534981A5 JP 2015534981 A5 JP2015534981 A5 JP 2015534981A5 JP 2015537809 A JP2015537809 A JP 2015537809A JP 2015537809 A JP2015537809 A JP 2015537809A JP 2015534981 A5 JP2015534981 A5 JP 2015534981A5
Authority
JP
Japan
Prior art keywords
dihydropyrazino
pyrazin
methyl
pyridin
triazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015537809A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015534981A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/065363 external-priority patent/WO2014062878A2/en
Publication of JP2015534981A publication Critical patent/JP2015534981A/ja
Publication of JP2015534981A5 publication Critical patent/JP2015534981A5/ja
Pending legal-status Critical Current

Links

JP2015537809A 2012-10-18 2013-10-17 Torキナーゼ阻害剤を用いた癌の治療 Pending JP2015534981A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261715510P 2012-10-18 2012-10-18
US61/715,510 2012-10-18
PCT/US2013/065363 WO2014062878A2 (en) 2012-10-18 2013-10-17 Treatment of cancer with tor kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019012014A Division JP7162543B2 (ja) 2012-10-18 2019-01-28 Torキナーゼ阻害剤を用いた癌の治療

Publications (2)

Publication Number Publication Date
JP2015534981A JP2015534981A (ja) 2015-12-07
JP2015534981A5 true JP2015534981A5 (enExample) 2016-11-24

Family

ID=50023830

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015537809A Pending JP2015534981A (ja) 2012-10-18 2013-10-17 Torキナーゼ阻害剤を用いた癌の治療
JP2019012014A Active JP7162543B2 (ja) 2012-10-18 2019-01-28 Torキナーゼ阻害剤を用いた癌の治療
JP2020199055A Pending JP2021050213A (ja) 2012-10-18 2020-11-30 Torキナーゼ阻害剤を用いた癌の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019012014A Active JP7162543B2 (ja) 2012-10-18 2019-01-28 Torキナーゼ阻害剤を用いた癌の治療
JP2020199055A Pending JP2021050213A (ja) 2012-10-18 2020-11-30 Torキナーゼ阻害剤を用いた癌の治療

Country Status (19)

Country Link
US (1) US20140113904A1 (enExample)
EP (1) EP2908814B1 (enExample)
JP (3) JP2015534981A (enExample)
KR (2) KR102267927B1 (enExample)
CN (2) CN110721186A (enExample)
AU (1) AU2013202768B2 (enExample)
BR (1) BR112015008834A2 (enExample)
CA (1) CA2888609C (enExample)
EA (1) EA029164B1 (enExample)
ES (1) ES2777936T3 (enExample)
IL (1) IL238326B (enExample)
MX (1) MX368407B (enExample)
MY (1) MY176599A (enExample)
NI (1) NI201500055A (enExample)
PH (2) PH12020550858A1 (enExample)
SG (2) SG11201502999YA (enExample)
UA (1) UA117000C2 (enExample)
WO (1) WO2014062878A2 (enExample)
ZA (1) ZA201503105B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
EP2945636B1 (en) 2013-01-16 2017-06-28 Signal Pharmaceuticals, LLC Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
US9737535B2 (en) 2014-04-16 2017-08-22 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
AU2015289929A1 (en) 2014-07-14 2017-03-02 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
JP6964343B2 (ja) * 2015-11-20 2021-11-10 フォーマ セラピューティクス,インコーポレイテッド ユビキチン特異的プロテアーゼ1阻害剤としてのプリノン
EP3641772B1 (en) 2017-06-22 2023-08-02 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
CN110403943B (zh) * 2019-08-19 2022-05-17 陕西科技大学 Cc-115在制备抗真菌药物中的应用及其药物组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1159582C (zh) * 2001-12-08 2004-07-28 云南大学 一种人体全血或血清总前列腺特征性抗原值,总前列腺特征性抗原灰区值检测方法
GB0509748D0 (en) 2005-05-13 2005-06-22 Univ Glasgow Materials and methods relating to cell based therapies
US20070238745A1 (en) * 2006-04-07 2007-10-11 University Of South Florida PI3K-Akt Pathway Inhibitors
ES2383370T3 (es) 2006-10-19 2012-06-20 Signal Pharmaceuticals Llc Compuestos de heteroarilo, sus composiciones y uso de los mismos como inhibidores de proteína quinasa
EP2457913B1 (en) * 2006-10-19 2017-04-19 Signal Pharmaceuticals, LLC Heteroaryl compounds, compositions thereof, and methods of treatment therewith
EP2349984A1 (en) * 2008-10-17 2011-08-03 Merck & Co. Combination therapy
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
JP2013508456A (ja) * 2009-10-26 2013-03-07 シグナル ファーマシューティカルズ, エルエルシー ヘテロアリール化合物の合成方法および精製方法
US20120238562A1 (en) * 2011-03-09 2012-09-20 Cedars-Sinai Medical Center Treatment of cancer by targeting molecules that influence mst1/stk4 signaling

Similar Documents

Publication Publication Date Title
RU2013108840A (ru) Биомаркерный анализ для детектирования или измерения ингибирования активности tor-киназы
JP2013518890A5 (enExample)
JP2015534981A5 (enExample)
JP7060694B2 (ja) Retキナーゼ阻害剤としての置換ピロロ[2,3-d]ピリミジン化合物
AU2013203156B2 (en) Treatment of cancer with TOR kinase inhibitors
RU2015105249A (ru) Ингибиторы mtor киназы для онкологических показаний и заболеваний, связанных с mtor/pi3k/akt путем метаболизма
JP2013508456A5 (enExample)
AU2011212927B2 (en) Identification of LKB1 mutation as a predictive biomarker for sensitivity to TOR kinase inhibitors
JP2016516817A5 (enExample)
JP2016516820A5 (enExample)
AU2013203714B2 (en) Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
JP2016516819A5 (enExample)
TW201343166A (zh) 使用tor之激酶抑制劑之癌症治療
JP2021511315A (ja) RETキナーゼ阻害剤としての置換ピラゾロ[3,4−d]ピリミジン化合物
JP2021511330A (ja) Retキナーゼ阻害剤としての置換ピラゾリル[4,3−c]ピリジン化合物
MX2014011077A (es) Tratamiento de cancer con inhibidores de tor cinasa.
TW201343165A (zh) 使用tor激酶抑制劑之癌症治療
CN110721186A (zh) 利用tor激酶抑制剂治疗前列腺癌
HK40013177A (en) Treatment of prostate cancer with tor kinase inhibitors
AU2015213397A1 (en) Treatment of cancer with TOR kinase inhibitors